Back to News
Market Impact: 0.2
Ex-OpenAI Science Head Kevin Weil Launches Startup With $215 Million
Source: Bloomberg
Artificial IntelligenceHealthcare & BiotechTechnology & InnovationPrivate Markets & Venture
Former OpenAI executive Kevin Weil is launching a startup that aims to use AI to accelerate a key step in drug development. The article provides no details on funding, the specific development step, or expected commercial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Wake up! The long bond’s up two points!
- US tech stocks tumble as investors fret over AI spending
- Asian shares wobble as tech rout boosts bonds, dents rate hike bets
- AI debt and French bonds face a stress test — why it may not be over
- Nasdaq 100 Drops as Oil Rise Fuels Risk-Off Mood
- U.S. plans curbs on Chinese tech investment- these sectors are vulnerable